Anivive Lifesciences, a software-driven pet pharmaceutical company headquartered in Long Beach, California, announced on Valentine’s Day the successful completion of its field study to evaluate the safety and effectiveness of Laverdia-CA1 verdinexor tablets in dogs with lymphoma. The randomized, placebo-controlled, double-masked study conducted at 12 clinical trial sites across the USA enrolled 150 dogs selected from more than 700 applicants using AniviveTrial. The company said the final study site was closed on December 12, marking...